Rep. Maria Elvira Salazar Buys Moderna, Inc. (NASDAQ:MRNA) Shares

Posted by Nicole Kennedy on Sep 12th, 2026

Representative Maria Elvira Salazar (Republican-Florida) recently bought shares of Moderna, Inc. (NASDAQ:MRNA). In a filing disclosed on September 09th, the Representative disclosed that they had bought between $1,001 and $15,000 in Moderna stock on August 19th. The trade occurred in the Representative’s “UBS IRA ACCOUNT” account.

Representative Maria Elvira Salazar also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of International Business Machines (NYSE:IBM) on 8/24/2026.
Sold $1,001 – $15,000 in shares of Moderna (NASDAQ:MRNA) on 8/19/2026.
Sold $1,001 – $15,000 in shares of Qualcomm (NASDAQ:QCOM) on 8/19/2026.
Purchased $15,001 – $50,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 8/19/2026.
Sold $15,001 – $50,000 in shares of Chubb (NYSE:CB) on 8/19/2026.
Sold $1,001 – $15,000 in shares of Qualcomm (NASDAQ:QCOM) on 8/12/2026.
Purchased $1,001 – $15,000 in shares of SpaceX (NASDAQ:SPCX) on 8/12/2026.
Purchased $1,001 – $15,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 8/7/2026.
Purchased $1,001 – $15,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 7/28/2026.
Purchased $15,001 – $50,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 7/28/2026.

Moderna Price Performance

Shares of MRNA traded up $7.35 during trading hours on Friday, reaching $143.97. The stock had a trading volume of 15,383,796 shares, compared to its average volume of 33,437,252. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $176.66. The stock has a market capitalization of $57.48 billion, a PE ratio of -18.02 and a beta of 1.10. The company’s 50-day moving average is $92.35 and its two-hundred day moving average is $66.74.

Moderna (NASDAQ:MRNA – Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.03) by $0.06. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%.The business had revenue of $145.00 million for the quarter, compared to analyst estimates of $102.93 million. During the same quarter in the previous year, the company posted ($2.13) EPS. Moderna’s quarterly revenue was up 2.1% compared to the same quarter last year. Research analysts expect that Moderna, Inc. will post -6.09 EPS for the current year.

Wall Street Analyst Weigh In

MRNA has been the topic of a number of recent research reports. Piper Sandler reiterated an “overweight” rating on shares of Moderna in a report on Monday, August 3rd. William Blair assumed coverage on Moderna in a report on Friday, August 28th. They issued an “outperform” rating for the company. Brookline Capital Markets reaffirmed a “buy” rating on shares of Moderna in a research report on Wednesday, August 19th. Morgan Stanley lifted their target price on Moderna from $39.00 to $89.00 and gave the stock an “equal weight” rating in a report on Thursday, August 20th. Finally, Jefferies Financial Group reiterated a “hold” rating on shares of Moderna in a research report on Wednesday, August 19th. Seven analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have assigned a Sell rating to the company. Based on data from MarketBeat, Moderna has a consensus rating of “Hold” and an average price target of $76.72.

Get Our Latest Report on Moderna

Moderna News Summary

Here are the key news stories impacting Moderna this week:

Positive Sentiment: Momentum and upcoming data readouts supported the stock. Moderna rallied in Friday morning trading despite limited movement among peers. UBS reportedly identified three near-term “INT” data readouts, potentially giving investors multiple upcoming catalysts to anticipate. However, the reports did not provide detailed results or confirm that any readout will be positive. Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat Moderna Set for 3 Near-Term INT Data Readouts, UBS Says
Neutral Sentiment: Congressional trading coverage offers no clear Moderna-specific catalyst. A report discussing recent stock transactions by members of Congress included Moderna-related investor-monitoring activity, but it did not identify a material change in the company’s outlook or operations. Congressional Stock Transactions
Neutral Sentiment: Short-interest data appears unreliable. The report listed both current and prior short interest at zero and calculated a zero-day short-interest ratio, with an invalid percentage change. Therefore, it provides little useful information about short-covering or bearish positioning in Moderna.
Negative Sentiment: Industry commercialization hurdles remain a risk. Manufacturing complexity and other barriers could slow the development and commercialization of personalized mRNA cancer vaccines, highlighting longer-term execution risks for Moderna and its peers. mRNA Cancer Vaccines’ Biggest Barriers to Market

Insider Transactions at Moderna

In other news, insider Shannon Klinger sold 3,471 shares of the firm’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the completion of the sale, the insider owned 74,129 shares in the company, valued at $10,374,353.55. This trade represents a 4.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of Moderna stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the sale, the president directly owned 1,483,848 shares in the company, valued at $76,225,271.76. This trade represents a 3.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.80% of the stock is owned by insiders.

Institutional Trading of Moderna

Several hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in Moderna in the 2nd quarter valued at $2,142,877,000. California State Teachers Retirement System increased its holdings in Moderna by 6,698.1% during the second quarter. California State Teachers Retirement System now owns 27,681,318 shares of the company’s stock worth $1,938,523,000 after buying an additional 27,274,128 shares during the last quarter. Capital World Investors purchased a new stake in Moderna during the fourth quarter worth about $378,299,000. Theleme Partners LLP bought a new stake in Moderna in the second quarter worth about $564,272,000. Finally, Alyeska Investment Group L.P. bought a new stake in Moderna in the fourth quarter worth about $95,209,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida’s 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida’s 27th Congressional District. She won in the general election on November 5, 2024.

Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

About Moderna

(Get Free Report)

Moderna, Inc is a biotechnology company that develops messenger RNA (mRNA) medicines and vaccines. Its platform is designed to provide cells with instructions to produce proteins that may help prevent or treat infectious diseases, cancer and other medical conditions.

The company’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. Moderna also maintains a pipeline of investigational programs in areas such as seasonal influenza, cytomegalovirus, oncology and rare diseases.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets in the United States and internationally through regulatory approvals, commercial partnerships and distribution arrangements.